BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 13.3//EN BEGIN:VTIMEZONE TZID:UTC BEGIN:STANDARD DTSTART;VALUE=DATE:20230101 TZNAME:UTC TZOFFSETFROM:+0000 TZOFFSETTO:+0000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:CHAIR: Stephen Pyke\, GSK Speaker: Kayode Ogungbenro\, Centre for Applied Pharmacokinetic Research\, The University of Manchester\nAppli cation of optimal design methodologies in clinical pharmacology experiment s \nCo-authors: Aristides Dokoumetzidis and Leon Aarons\; \nPharmaceutical Statistics\, Volume 8\, Issue 3\, Pages 239&ndash\;252\, July/September 2 009 Abstract | Paper+ | Slides \; \nSpeaker: Simon Kirby\, Pfizer\nDis counting phase 2 results when planning phase 3 clinical trials\nCo-authors : J. Burke\, C. Chuang-Stein and C. Sin\; \nPharmaceutical Statistics\, Vo lume 11\, Issue 5\, Pages 373&ndash\;385\, September/October 2012 Abstract | Paper+ | Slides + Papers available to view from 29th November 2012 to 2 7th December 2012. \nFor a flier advertising the event\, please click her e.  \; DTEND:20121206T153000Z DTSTAMP:20240329T114444Z DTSTART:20121206T140000Z LOCATION: SEQUENCE:0 SUMMARY:Journal Club - Modelling in Drug Development UID:RFCALITEM638473094843975413 X-ALT-DESC;FMTTYPE=text/html:
CHAIR: Stephen Pyke\, GSK<
br />
Speaker: Kayode Ogungbenro\, Centre for Appl
ied Pharmacokinetic Research\, The University of Manchester
\nApplica
tion of optimal design methodologies in clinical pharmacology experiments
\nCo-authors: Aristides Dokoumetzidis and Leon Aarons\;
\nPhar
maceutical Statistics\, Volume 8\, Issue 3\, Pages 239&ndash\;252\, July/S
eptember 2009
Abstract | Paper+ | Sli
des \;
\nSpeaker: Simon Kirby\, Pfize
r
\nDiscounting phase 2 results when planning phase 3 clinical trials
\nCo-authors: J. Burke\, C. Chuang-Stein and C. Sin\;
\nPharma
ceutical Statistics\, Volume 11\, Issue 5\, Pages 373&ndash\;385\, Septemb
er/October 2012
Abstract | Paper+ | Slides